Salesforce for antibody discovery

AWS for drug R&D

• Antibody Discovery Platform Services: AbCellera offers its full-stack, AI-powered platform to partners for the identification and discovery of novel therapeutic antibodies, which are then developed as drugs.

AbCellera Biologics (ABCL) sells primarily to other companies in the pharmaceutical and biotechnology sectors. Based on the provided information, a major customer is:

• Eli Lilly and Company (LLY)

Carl L.G. Hansen

Chief Executive Officer and President

Dr. Carl Hansen is the founding CEO of AbCellera. He was appointed in November 2012. Before leading AbCellera, he co-founded Precision Nanosystems, a company focused on developing next-generation delivery technology for genetic medicines, and served as its Chairman. He also served on the Scientific Advisory Board of Fluidigm Corp.. His work, which spans engineering, biology, and computation, is represented in numerous peer-reviewed manuscripts and over 75 patent applications, leading to nine successful commercial products.

Andrew Booth

Chief Financial Officer

Andrew Booth became AbCellera's CFO in 2019, after serving on the company's Board of Directors for nearly four years starting in 2016. Prior to joining AbCellera, he spent a decade at STEMCELL Technologies, holding roles as CFO and Chief Commercial Officer, where he contributed to the company's significant growth. Before STEMCELL, Mr. Booth spent seven years at General Electric, where he led mergers and acquisitions and business development for GE Healthcare's operations in Europe, the Middle East, Africa, and its global Life Sciences business. He is also an advisor to Aspect Biosystems and 5AM Venture Capital, and previously served as Chairman of Precision NanoSystems, Inc..

Véronique Lecault

Chief Technology Officer

Dr. Véronique Lecault is a Co-founder and Chief Technology Officer at AbCellera. She is also a member of the Board of Directors. She co-invented the high-throughput microfluidic platform that is a foundational component of AbCellera's antibody discovery technology. Dr. Lecault previously served as AbCellera's Chief Operating Officer from 2019 until her transition to CTO in February 2025, during which time she oversaw the company's growth.

Tryn Stimart

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer

Tryn Stimart is a seasoned executive with over 20 years of experience in the biotech and pharmaceutical industries. He joined AbCellera in 2019. His expertise covers corporate legal matters, mergers and acquisitions, financing, SEC and FDA regulatory processes, licensing, privacy, commercial and patent litigation, and intellectual property strategy. Before his tenure at AbCellera, Mr. Stimart was a partner at Gibbons P.C., where he represented prominent biotech and pharma clients, and also held legal counsel positions at Finnegan LLP, Cooley LLP, and Womble Bond Dickinson LLP. He is also a former United States Naval Officer.

The key risks to AbCellera Biologics (ABCL) are primarily centered around its financial performance, the successful development of its internal drug pipeline, and its reliance on partnerships.

1. Financial Risks and Path to Profitability: AbCellera Biologics has a history of incurring net losses and substantial cash burn, driven by significant investments in research and development (R&D) to advance its own drug pipeline. The company is in a crucial and expensive transition from being primarily a technology partner to becoming a clinical-stage biotechnology firm. This strategic shift creates near-term financial strain, and its ability to generate sufficient revenue to achieve sustained profitability remains uncertain.
2. Clinical Development Risk and Internal Pipeline Success: As AbCellera increasingly focuses on developing its own drug candidates, it faces the inherent high failure rate, extensive costs, and lengthy timelines associated with clinical trials. The success of its internal programs, such as ABCL635 and ABCL575, is critical for future revenue generation and investor confidence. Setbacks in clinical development, even after promising early results, could materially impact the business and stock price.
3. Dependence on Partnerships and Revenue Volatility: A significant portion of AbCellera's historical and projected revenue still relies on its partners successfully developing and commercializing the antibodies discovered using its platform, as well as the achievement of milestone payments. This dependence on external parties for revenue generation introduces volatility and exposes the company to risks related to partner performance and decisions. The company's past reliance on COVID-related antibodies developed with Eli Lilly, which are no longer authorized, exemplifies this risk.

AbCellera Biologics Inc. (symbol: ABCL) operates within the addressable markets of antibody discovery and monoclonal antibody therapeutics. The company's core business, leveraging its artificial intelligence-powered platform, directly contributes to the antibody discovery market, while the antibodies developed, both for partners and through its internal pipeline, target the broader monoclonal antibody therapeutics market.

The estimated addressable market sizes for AbCellera Biologics' main products or services are as follows:

• Global Antibody Discovery Market: This market, which directly relates to AbCellera's antibody discovery platform services, was valued at approximately USD 9.09 billion in 2025. It is projected to reach around USD 15.45 billion by 2030, and is anticipated to surpass USD 20.43 billion by 2034. Other estimates place the market at approximately USD 22.28 billion by 2035.
• Global Monoclonal Antibody Therapeutics Market: This market represents the drugs that are discovered and developed using platforms like AbCellera's. It was estimated to be around USD 233.19 billion in 2024 and is expected to reach approximately USD 631.3 billion by 2030. Projections further indicate growth to around USD 919.06 billion by 2033 or potentially USD 973.60 billion by 2034.

Expected Drivers of Future Revenue Growth for AbCellera Biologics (ABCL)

Over the next 2-3 years, AbCellera Biologics (ABCL) is expected to drive future revenue growth through several key initiatives, primarily stemming from its strategic transition to a clinical-stage biotechnology firm and the continued leverage of its antibody discovery platform.

1. Advancement of Proprietary Clinical Pipeline: A significant driver of future revenue is the progression of AbCellera's internal drug candidates through clinical trials. The company is heavily investing in its proprietary pipeline, with lead programs such as ABCL635 in Phase 2 studies for vasomotor symptoms, ABCL575 in Phase 1 trials for autoimmune disorders, and ABCL688 and ABCL386 advancing through IND-enabling activities. Positive clinical readouts and the successful advancement of these programs are anticipated to generate substantial milestone payments and, eventually, royalties from commercialization.
2. Increased Milestone and Royalty Payments from Partnered Programs: AbCellera's business model includes payments tied to the success of drug candidates discovered through its platform for partners. As partnered molecules advance through various clinical stages and, ultimately, commercialization, the company stands to receive significant milestone payments and future royalties. For example, Q4 2025 revenue included $48 million from licensing and royalties, and licensing revenue saw a significant surge over the nine months ending September 30, 2025.
3. Revenue Generation from Clinical Manufacturing Facility: The completion of AbCellera's Good Manufacturing Practice (GMP) clinical manufacturing facility, expected to be fully operational by early 2026, represents a new revenue stream. This facility will not only support the in-house development of AbCellera's own drug candidates but also has the potential to offer contract development and manufacturing organization (CDMO) services to external partners, thereby diversifying revenue sources.
4. Growth in Partner-Initiated Programs and Associated Research Fees: While the company is pivoting towards its internal pipeline, the continued growth in partner-initiated discovery programs remains a contributor to revenue. An increase in the number of programs initiated by partners, such as the rise to a cumulative total of 90 partner-initiated program starts in Q1 2024 from 75 in Q1 2023, generates research fees for AbCellera.

Share Repurchases

Share Issuance

• In December 2020, AbCellera completed its Initial Public Offering (IPO), raising approximately $555.5 million in gross proceeds through the issuance of 27,772,500 common shares.
• Concurrently with its IPO in December 2020, previously issued convertible promissory notes totaling approximately $90.0 million were converted into 6,093,524 common shares.
• In June 2021, certain selling shareholders, including AbCellera's CEO, engaged in a secondary private sale of 11.9 million common shares, from which AbCellera Biologics itself did not receive any proceeds.

Inbound Investments

• AbCellera received CAD $175.6 million (approximately $125.6 million USD) in committed government funding from the Canadian government's Strategic Innovation Fund in April 2020, with a significant portion allocated towards building a Good Manufacturing Practices (GMP) facility.
• The company's Initial Public Offering (IPO) in December 2020 generated approximately $555.5 million in gross proceeds, representing a substantial capital infusion.
• As of fiscal year 2025, AbCellera reported approximately $700 million in total available liquidity, which includes cash, cash equivalents, marketable securities, and available non-dilutive government funding, positioning the company to fund its pipeline investments for well over three years.

Outbound Investments

• In November 2020, AbCellera acquired Trianni for $90.0 million to enhance its antibody generation capabilities through transgenic mouse technology.
• AbCellera is a founding partner and holds equity in Abdera, a company with a lead program, ABD-147, for which AbCellera also receives royalties.
• The company has made significant and aggressive Research & Development (R&D) investments, with expenses totaling $186.8 million in fiscal year 2025, primarily focused on advancing its internal drug pipeline and technology platform.

Capital Expenditures

• AbCellera has undertaken substantial capital expenditures related to its infrastructure, including a global headquarters expansion and the construction of a 130,000-square-foot Good Manufacturing Practices (GMP) manufacturing facility in Vancouver.
• Construction of the GMP facility began in June 2021, with activities commencing in Q3 2025, aimed at producing therapeutic antibodies for clinical trials and enhancing operational efficiency.
• Capital expenditures were approximately -$42.77 million in the last 12 months as of late 2025.